home.social

#gsk — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #gsk, aggregated by home.social.

  1. GSK Lands Its First Lung Cancer Drug Days After Nuvalent Deal Closes — BigGo Finance

    GSK had never won FDA approval for a lung cancer drug — not in decades of trying. Then,…
    #EuropeSays #Britain #Europe #EU #GSK #AxiomBiosciences #FDA #FierceBiotech #HongKongExchange #Jideytro #MarissaRusso #nasdaq #Nuvalent #TheTopLine #U.S.HouseofRepresentatives
    europesays.com/britain/89781/

  2. GSK admits 70,759 new shares to London market | GSK SEC Filing

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
    #EuropeSays #Britain #Europe #EU #GSK #admissiontotrading #blocklisting #Form6-K #GSKplc #LondonStockExchange #ordinaryshares #ShareSavePlan2022
    europesays.com/britain/89766/

  3. GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval

    Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
    #EuropeSays #Britain #Europe #EU #GSK #GSKstock #stockportfolio
    europesays.com/britain/89749/

  4. GSK executive acquires 9.4 notional ADS in plan | GSK SEC Filing

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
    #EuropeSays #Britain #Europe #EU #GSK #ADS #AmericanDepositaryShares #executivesupplementalsavingsplan #Form6-K #GSKplc #insidertransaction #MayaMartinez-Davis #NYSE
    europesays.com/britain/89735/

  5. Rx Rundown: Samsung Biologics, Dimension, GSK and more

    Deals: Samsung Biologics to buy Swiss PolyPeptide Group in a $1.8 billion deal. Tempus bought out cancer genomics…
    #EuropeSays #Britain #Europe #EU #GSK
    europesays.com/britain/89605/

  6. GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval

    Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
    #EuropeSays #Britain #Europe #EU #GSK #non-smallcelllungcancer #shareprice #totalshareholderreturn
    europesays.com/britain/89589/

  7. ‘I had dreams’: How HIV care has evolved across a generation

    In 2025, almost 41 million people were living with HIV worldwide, according to UNAIDS, with over half living…
    #EuropeSays #Britain #Europe #EU #GSK
    europesays.com/britain/89539/

  8. europesays.com/britain/89539/ ‘I had dreams’: How HIV care has evolved across a generation #GSK

  9. GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval

    Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
    #EuropeSays #Britain #Europe #EU #GSK #GSKstock #stockportfolio
    europesays.com/britain/89514/

  10. How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And Wider Risk Signals

    Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
    #EuropeSays #Britain #Europe #EU #GSK #HowConsumerStocksAreReadingTodayThroughGSK(LSE:GSK)AndWiderRiskSignals
    europesays.com/britain/89441/

  11. Samsung Biologics First-Half Operating Profit Tops ₩1 Trillion; Annual Revenue of ₩5 Trillion Within Reach — BigGo Finance

    Samsung Biologics (207940) has surpassed ₩1 trillion (approximately $678.2 million) in half-year operating profit for the first time…
    #EuropeSays #Korea #KR #SamsungBiologics #BioCampus3 #Celltrion #GLP-1 #GSK #JohnRim #Netherlandssalesoffice #peptide #Plant5 #PolyPeptideGroup #Rockvilleproductionfacility #Samsung
    europesays.com/korea/97114/

  12. How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And London Risk Signals

    Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
    #EuropeSays #Britain #Europe #EU #GSK
    europesays.com/britain/89349/

  13. europesays.com/britain/89349/ How Consumer Stocks Are Reading Today Through GSK (LSE:GSK) And London Risk Signals #GSK

  14. GSK shelves cough drug acquired in $2B deal

    This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
    #EuropeSays #Britain #Europe #EU #GSK #chroniccough #coughmedicine #irritablebowelsyndrome #TreviTherapeutics
    europesays.com/britain/89320/

  15. Is GSK (LSE:GSK) Undervalued Following Jideytro Approval?

    The latest move in GSK (LSE:GSK) stock interest is tied to the early US FDA approval of Jideytro…
    #EuropeSays #Britain #Europe #EU #GSK
    europesays.com/britain/89306/

  16. GSK (LSE:GSK) Wins FDA Nod For Jideytro As Bexsero And Jemperli Advance

    Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
    #EuropeSays #Britain #Europe #EU #GSK #Bexsero #Jemperli #Jideytro #Lungcancer #meningococcaldisease #Oncology #rectalcancer
    europesays.com/britain/89247/

  17. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

    Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or…
    #EuropeSays #Britain #Europe #EU #GSK #Biotechnology #ClinicalTrials&MedicalDiscoveries #FDAapproval #GSKplc #HealthCare&Hospitals #MedicalEquipment #MedicalPharmaceuticals #Pharmaceuticals
    europesays.com/britain/88598/

  18. $10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval

    A drug included in one of the pharmaceutical industry’s largest acquisitions this year is starting to paying dividends…
    #EuropeSays #Britain #Europe #EU #GSK #biopharmanl #Cancer #ClinicalTrials #FDA #Lungcancer #non-smallcelllungcancer #Nuvalent #Spotlight-payeropp
    europesays.com/britain/88582/

  19. FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule – GSK (NYSE:GSK)

    On Wednesday, the U.S. Food and Drug Administration (FDA) granted early approval to GSK plc’s (NYSE:GSK) targeted lung…
    #EuropeSays #Britain #Europe #EU #GSK #category:Biotech #category:FDA #category:General #category:HealthCare #category:LargeCap #category:News #CMS:WordPress #PageIsBzPro:BZ #symbol:GSK
    europesays.com/britain/88336/

  20. europesays.com/britain/88336/ FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule – GSK (NYSE:GSK) #Category:Biotech #Category:FDA #Category:General #Category:HealthCare #Category:LargeCap #Category:News #CMS:WordPress #GSK #PageIsBzPro:BZ #Symbol:GSK

  21. A-Alpha Bio Announces Industry-First Data Consortium to Solve AI Protein Engineering’s Experimental Data Bottleneck. Founding members include GSK, Boltz, Cradle, and Dyno Therapeutics.

    Consortium members will steer the experimental design with A-Alpha Bio to generate the large-scale, standardized antibody-antigen affinity and…
    #EuropeSays #Britain #Europe #EU #GSK #A-Alpha #ai #Announces #Bio #Consortium #Data #engineering #Industry-First #protein #Solve #to
    europesays.com/britain/88078/

  22. europesays.com/britain/88078/ A-Alpha Bio Announces Industry-First Data Consortium to Solve AI Protein Engineering’s Experimental Data Bottleneck. Founding members include GSK, Boltz, Cradle, and Dyno Therapeutics. #AAlpha #ai #Announces #Bio #Consortium #Data #engineering #GSK #IndustryFirst #protein #Solve #to

  23. By mid-2027, analysts expect £6,000 in GSK shares to be worth…

    After a major move higher in the second half of 2025 and early 2026, GSK (LSE: GSK) shares…
    #EuropeSays #Britain #Europe #EU #GSK #analysts #FTSE100index #GSKplc #GSKshares #Johnson&Johnson #pricetarget #pricetargets #shareprice
    europesays.com/britain/87213/

  24. Halifax

    Important information Halifax Share Dealing Limited. Registered in England and Wales no. 3195646. Registered Office: Trinity Road, Halifax,…
    #EuropeSays #Britain #Europe #EU #GSK #BrokerOnLine
    europesays.com/britain/86383/

  25. EMA Accepts GSK’s Bexsero Booster Label Update for Single-Dose Meningitis B Vaccine in Individuals Aged 10 and Above

    Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions,…
    #EuropeSays #Britain #Europe #EU #GSK
    europesays.com/britain/86370/

  26. GSK Discontinues Development of Camlipixant for Refractory Chronic Cough

    GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, for the…
    #EuropeSays #Britain #Europe #EU #GSK #chroniccough #development #EPSestimates #GSKplc #ZacksInvestmentResearch
    europesays.com/britain/85910/

  27. GSK ends camlipixant RCC program after mixed results | GSK SEC Filing

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
    #EuropeSays #Britain #Europe #EU #GSK #BALANCEtrial #CALM-1 #CALM-2 #camlipixant #GSKplc #IBS-D #PhaseIIItrials #refractorychroniccough #SECForm6-K
    europesays.com/britain/85320/